The rats were divided into three groups:
1. control group
2. group I (thyroxine was administered 300 μg per day for a week)
3. group II (thyroxine was administered 300 μg per day for two weeks)

Results:
1. Hemesynthetase activity in hyperthyroidism was as low as one sixth of normals.
2. Plasma iron disappearance half-time (PIDT 1/2) was as follows:
   - control: 97.0±20.0 min.
   - group I: 104.0±23.5 min.

The Treatment of the Thyroid Cancer with Radioactive Iodine

M. Miyakawa, A. Muramatsu, M. Makiuchi and R. Furihata

Department of Surgery, Faculty of Medicine, Shinshu University, Matsumoto

We reported our clinical examples in treating distant metastasis of the thyroid tumors with radioactive iodine. We treated 4 patients with radioactive iodine. Of the 4 patients, 1 had papillary adenocarcinoma, 1 had follicular carcinoma, 1 had trabecular carcinoma, and 1 had tublar adenoma (so-called malignant adenoma). Out of them, in 3 cases our treatment with radioactive iodine were effective on their X-ray films.

We consider that radioactive iodine is an important therapeutic agent in selected cases of metastatic thyroid cancer.

Tissue Concentration of 131I-Toluidine Blue in Rats and Dogs with Special Reference to the Parathyroid Concentrations by Intracardiac and Intravenous Administration

M. Akisada

Department of Radiology, Mitsui Memorial Hospital, Tokyo

Y. Fujimoto

Second Department of Surgery, University of Tokyo, Tokyo

Tissue concentration of 131I-toluidine blue was studied in rats and dogs after intracardiac and intravenous injection. The parathyroid-thyroid ratio and parathyroid-neck muscle ratio was significantly higher in rats only after intracardiac injection. Neither intracardiac nor intravenous injection of 131I-toluidine blue (including infusion) gave a high parathyroid-thyroid ratio in dogs as compared to intravenous injection in rats.
<table>
<thead>
<tr>
<th>Tissue Specimen-Blood Ratio (Mean Values)</th>
</tr>
</thead>
<tbody>
<tr>
<td>parathyroid</td>
</tr>
<tr>
<td>Group I</td>
</tr>
<tr>
<td>Group II</td>
</tr>
<tr>
<td>Group III</td>
</tr>
<tr>
<td>Group IV</td>
</tr>
</tbody>
</table>